Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinovac Reports 39% Higher 2008 Revenues

publication date: Apr 10, 2009

Sinovac Biotech (北京科兴生物制品有限公司) reported that revenues from its vaccines rose 39% in 2008 to $46.5 million, while net income increased by a relatively small 5% to $8 million. A full 88% of the company’s 2008 sales came from Healive®, its hepatitis A vaccine that has long been Sinovac’s mainstay product. Sinovac said it expects 2009 revenues to increase a further 20% to a range of $55 million to $60 million. More details...

Stock Symbol: (NYSE Amex: SVA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital